Dublin, June 30, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "The Global Pain Therapeutics Market, 5th Edition: Market Trends & R&D Insights" report to their offering.
The pain therapeutics market is crowded and heavily genericized. In 2015, the leading branded pain therapeutics market was worth $11.3 billion, down 13.5% from 2014 total revenues of $13.1 billion.
Opioids form the backbone of pain management. This trend is set to continue over the coming years thanks to their continued superior analgesic activity. Physicians should become increasingly more confident in prescribing opioids due the arrival of abuse-deterrent formulations. By 2020, the leading branded opioids will generate over $6.6 billion in worldwide revenues.
Pain R&D is challenging, expensive and reliant on subjective outcome measures. Therefore, industry must revise their R&D strategies to gain success in this market. The FDA's 2014 Draft Guidance for Industry Analgesic Indications: Developing Drug and Biological Products should provide some clarity for pain developers, as this was indeed the first guidance update in over 20 years.
Purchase of Global Pain Therapeutics Market, 5th Edition: Market Trends and R&D Insights 2015 will enable you to:
- Assess opportunities and challenges influencing strategic pain R&D
- Identify leading branded pain therapeutics and key pipeline candidates in late-stage development based on sales forecasts to 2020 to maximize your products commercial potential
- Gain an impartial perspective of strategies that can be used to enhance your products performance in the pain market
Key questions answered by Arrowhead's Global Pain Therapeutics Market, 5th Edition: Market Trends and R&D Insights 2015 include:
- What are the major unmet needs in the current pain market?
- What are the leading potential pain biomarkers?
- What are the major challenges involved in the pain market and how can they be overcome?
- Who are the key players involved in the pain market and what business models are they using to raise company performance?
- How can players optimize strategic pain R&D to maximize commercial success?
- What recommendations does Arrowhead provide for successful pain R&D?
- What are the leading branded pain therapeutics available on the market?
- What are the key leading therapeutic candidates in the pain pipeline?
- How much revenue will the leading branded analgesic products reach by 2020?
- How much revenue will the key pipeline drug candidates reach by 2020?
- What does the future hold for the pain market?
Key Topics Covered:
1 Executive Summary
2 Pain: Disease Background
3 Managing Pain: Who's Pain Therapeutics Classes And Treatment Guidelines
4 The Postoperative Pain Market
5 The Neuropathic Pain Market
6 The Fibromyalgia Market
7 The Arthritic Pain Market
8 The Migraine Market
9 The Cancer Pain Market
10 The Back Pain Market
11 Pain Therapeutics Research And Development Trends
12 Unmet Needs In The Pain Therapeutics Market
13 Pain Therapeutics Pipeline Watch
14 Analysis Of The Pain Therapeutic Market
15 Company Briefs
- Abbvie Inc.
- Acelrx Pharmaceuticals Inc.
- Acorda Therapeutics Inc.
- Adynxx
- Alder Biopharmaceuticals Inc.
- Allergan
- Amgen Inc.
- Astellas Pharmaceuticals Inc.
- AstraZeneca
- Avanir Pharmaceuticals Inc.
- Biogen Inc.
- Biosciences Delivery International Inc.
- COLLEGIUM Pharmaceutical Inc.
- Colucid Pharmaceuticals Inc.
- Daiichi Sankyo Company Ltd.
- Depomed Inc.
- Durect Corporation
- Eli Lilly and Company
- Endo Pharmaceuticals Inc.
- Epirus Biopharmaceuticals
- Galapagos NV
- Galena Biopharma
- GW Pharmaceuticals PLC
- Horizon Pharma PLC
- Hospira Inc.
- Incyte Corporation
- Immune Pharmaceuticals
- Impax Laboratories
- Insys Therapeutics Inc.
- Johnson & Johnson
- Meda AB
- Mesoblast Ltd.
- Novartis International AG
- Optinose US Inc.
- Pacira Pharmaceuticals Inc.
- Pernix Therapeutics Holdings Inc.
- Pfizer Inc.
- Proove Biosciences Inc.
- Pozen Inc.
- Prostrakan Group
- Purdue Pharmaceuticals LP
- Regeneron Pharmaceuticals Inc.
- Sanofi
- Spinifex Pharmaceuticals Pty Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Theravance Biopharma
- Tonix Pharmaceuticals
- Trevena Inc.
- Trigemina Inc.
- WEX Pharmaceuticals
- Yichang Humanwell Pharmaceutical Co. Ltd.
For more information visit http://www.researchandmarkets.com/research/k93bcm/the_global_pain